Suppr超能文献

COVID-19大流行对美国专科治疗的重度哮喘患者哮喘急性加重和住院发生率的影响:CHRONICLE研究结果

Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study.

作者信息

Moore Wendy C, Ledford Dennis K, Carstens Donna D, Ambrose Christopher S

机构信息

Wake Forest School of Medicine Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Winston-Salem, NC, USA.

Morsani College of Medicine, University of South Florida, and James A. Haley Veterans' Hospital, Tampa, FL, USA.

出版信息

J Asthma Allergy. 2022 Aug 31;15:1195-1203. doi: 10.2147/JAA.S363217. eCollection 2022.

Abstract

PURPOSE

Patients with severe asthma (SA) are at an increased risk of asthma-related hospitalizations and exacerbations. Despite concerns that COVID-19 circulation would increase exacerbations of SA, anecdotal reports suggest that social distancing and exposure avoidance may have led to reduced exacerbations.

PATIENTS AND METHODS

CHRONICLE is an ongoing noninterventional observational study of 3100 subspecialist-treated patients with SA. Eligible adults (≥ 18 years of age) have (1) current use of monoclonal antibody (ie, biologic) therapy for SA, (2) use of maintenance systemic corticosteroids (mSCS) or other systemic immunosuppressants for ≥ 50% of the prior 12 months for SA, or (3) persistently uncontrolled asthma while treated with high-dosage inhaled corticosteroids with additional controllers. For enrolled patients, electronic medical records were reviewed to record all exacerbations and asthma-related hospitalizations. Descriptive analyses were conducted of the monthly incidence of exacerbations, exacerbation-related visits to the emergency department (ED), and asthma hospitalizations from July 2018 through July 2021.

RESULTS

Exacerbations, exacerbation-related ED visits, and hospitalizations decreased since April 2020. Exacerbations in 2020 were 20% to 52% lower in April through August relative to the same months in 2019. Exacerbations remained lower than the prior year through May 2021. Similar results were observed by United States (US) census region, with an earlier decrease in exacerbation rates in the western US versus other regions. Across all months, exacerbation rates were lower among biologic recipients.

CONCLUSION

In a clinical cohort of subspecialist-treated patients with SA, there was a meaningful reduction in exacerbations, exacerbation-related ED visits, and asthma hospitalizations following COVID-19-related stay-at-home orders and social distancing recommendations. Reasons for these reductions are likely multifactorial, including reduced viral infections due to less social contact and altered patient behavior.

摘要

目的

重度哮喘(SA)患者哮喘相关住院和病情加重的风险增加。尽管有人担心2019冠状病毒病(COVID-19)传播会增加SA病情加重,但轶事报道表明,社交距离和避免接触可能导致病情加重减少。

患者与方法

CHRONICLE是一项正在进行的针对3100例接受专科治疗的SA患者的非干预性观察性研究。符合条件的成年人(≥18岁)具备以下情况之一:(1)目前正在使用单克隆抗体(即生物制剂)治疗SA;(2)在过去12个月中≥50%的时间使用维持性全身用糖皮质激素(mSCS)或其他全身免疫抑制剂治疗SA;或(3)在接受高剂量吸入性糖皮质激素及其他控制药物治疗时哮喘持续未得到控制。对于入组患者,查阅电子病历以记录所有病情加重情况及哮喘相关住院情况。对2018年7月至2021年7月期间病情加重的月发病率、与病情加重相关的急诊就诊情况及哮喘住院情况进行了描述性分析。

结果

自2020年4月起,病情加重情况、与病情加重相关的急诊就诊及住院情况均有所减少。2020年4月至8月的病情加重情况相较于2019年同期降低了20%至52%。直至2021年5月,病情加重情况仍低于上一年。美国人口普查区域观察到类似结果,美国西部病情加重率的下降早于其他地区。在所有月份中,接受生物制剂治疗的患者病情加重率较低。

结论

在一组接受专科治疗的SA患者临床队列中,在与COVID-19相关的居家令和社交距离建议发布后,病情加重情况、与病情加重相关的急诊就诊及哮喘住院情况均有显著减少。这些减少的原因可能是多方面的,包括社交接触减少导致病毒感染减少以及患者行为改变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7396/9441176/b3213c31e72f/JAA-15-1195-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验